Amer Zeidan

Amer Zeidan, MBBS, MHS, is a Professor of Medicine at Yale School of Medicine and Chief of the Division of Hematologic Malignancies. He leads the Leukemia and Myeloid Malignancies Program at Yale Cancer Center, focusing on novel therapies for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). His work spans clinical trials, drug development, and precision medicine, with over 360 peer-reviewed publications.

• Education: MBBS (University of Jordan), MHS (Johns Hopkins University)
• Affiliations: Yale Cancer Center, Department of Internal Medicine
• Roles: Director of Early Therapeutics Research, Co-Leader of the Leukemia & Myeloid Malignancies Clinical Research Team

Research interests include targeted therapies, immunotherapy, and improving clinical trial accessibility. Dr. Zeidan chairs multiple national/international initiatives, including the International Consortium for MDS (icMDS) and the MyeloMATCH precision medicine program.

Awards: Leukemia & Lymphoma Society Scholar Award, NCI Clinical Investigator Leadership Award, ASCO Young Investigator Award.

His lab collaborates with global teams to advance treatments, with ongoing trials in combination therapies and immune checkpoint inhibitors. He also emphasizes reducing disparities in MDS/AML care through guideline development and global partnerships.